Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, ...
Texas Biomedical Research Institute has established a new $2 million Tuberculosis Innovation and Technology Fund supported by philanthropic investment to accelerate future TB discoveries, therapies ...
SAN ANTONIO, April 20, 2026 /PRNewswire/ -- Texas Biomedical Research Institute is advancing new tools -- known as new approach methodologies (NAMs) -- that can accelerate discoveries and drug ...
Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
The latest study results for the BackBeat cardiac neuromodulation therapy device are music to Orchestra BioMed’s ears. The implant is meant to integrate with a patient’s existing pacemaker or other ...
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today ...
SAN ANTONIO – The Texas Biomedical Research Institute has withdrawn its $11 million request for bond funding in the face of public outcry over animal welfare concerns. Texas Biomed had requested money ...
BioMed Realty Trust continues to push the life sciences conversion wave in Boston, quietly taking over two prominent development sites. The Blackstone-backed life sciences investor has entered a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results